TICKERNERD
Menu
ALLOALLOHealthcare · Biotechnology

ALLO Stock Forecast: Allogene Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$2.05
+3.54% on the day

The 12 Wall Street analysts covering Allogene Therapeutics, Inc. hold a median 12-month price target of $9 — +339.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 79 of 100 as at 15 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$707.6M
Ticker Nerd rank
79 / 100
Median analyst target
$9.00
Analysts covering
12
Total return, dividends reinvested
1W
+2.0%
1M
+10.8%
YTD
+49.6%
1Y
+91.6%
From 52W high
−33.0%
From 52W low
+95.2%
$1.05
$3.06
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ALLO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Allogene Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
79 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
87
Quality
77
Growth
66
Accruals
63
Momentum
58
Value
55
Size
50
Issuance
45
Volatility
43

Revisions (87): Analysts have, on balance, been raising their forecasts.

Volatility (43): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ALLO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ALLO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00Oct 25Jan 26Apr 26Jul 26ALLOHigh $14.00Median $9.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says12 analysts
11 Buy1 Hold0 Sell
Low $4.00Median $9.00High $14.00

The green dot is the last close — the median target sits +339.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
16 Apr 2026HC Wainwright & Co.MaintainsBuy$12 → $11
16 Apr 2026HC Wainwright & Co.MaintainsBuy—
16 Apr 2026JP MorganUpgradeNeutral—
16 Apr 2026JP MorganUpgradeNeutral—
15 Apr 2026JefferiesMaintainsBuy$6.00 → $10
15 Apr 2026JefferiesMaintainsBuy—
14 Apr 2026Argus ResearchMaintainsMarket Perform—
14 Apr 2026Argus ResearchMaintainsMarket Perform$1.60 → $3.85
14 Apr 2026BairdMaintainsOutperform—
14 Apr 2026BairdMaintainsOutperform$7.00 → $9.00
14 Apr 2026BernsteinMaintainsMarket Perform—
14 Apr 2026BernsteinMaintainsMarket Perform$1.60 → $3.85
14 Apr 2026CitizensMaintainsMarket Outperform$5.00 → $8.00
14 Apr 2026CitizensMaintainsMarket Outperform—
14 Apr 2026HC Wainwright & Co.MaintainsBuy$8.00 → $12
14 Apr 2026HC Wainwright & Co.MaintainsBuy—
13 Mar 2026Canaccord GenuityMaintainsBuy—
13 Mar 2026Piper SandlerMaintainsOverweight—
9 Jan 2026CitizensUpgradeMarket Outperform—
7 Jan 2026UBSInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ALLO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ALLO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
1
Fundamentals

Allogene Therapeutics, Inc. (ALLO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.4×

Cheaper than 86% of US stocks

Price / sales
152.5×

Cheaper than 3% of US stocks

Price / book
1.6×

Cheaper than 54% of US stocks

EV / EBITDA
−2.7×

Cheaper than 73% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
−1011.2%

Higher than 5% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−42.4%

Higher than 23% of US stocks

Return on assets
−22.1%

Higher than 18% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ALLO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ALLOAllogene Therapeutics, Inc.$707.6M
79
ZVRAZevra Therapeutics, Inc.$664.6M
97
NGNENeurogene, Inc.$697.6M
60
RGNXREGENXBIO, Inc.$703.1M
56
TECXTectonic Therapeutic, Inc.$653.4M
52
ASMBAssembly Biosciences, Inc.$653.0M
86
SGMTSagimet Biosciences, Inc.$645.5M
30

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Allogene Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ALLO news & analysis

Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs

Zacks Investment Research · 13 Aug 2026positive

Allogene Therapeutics narrowed its Q2 loss as research and development costs declined, while a stronger cash position extended its projected runway into 2029. The company's quarterly earnings beat estimates on the lower R&D spending.

Why it matters — The reduced Q2 loss and extended cash runway into 2029 indicate improved financial stability for ALLO, a key factor for investors tracking the company's progress.

Allogene Therapeutics, Inc. (ALLO) Q2 2026 Earnings Call Transcript

Seeking Alpha · 12 Aug 2026neutral

Allogene Therapeutics held its Q2 2026 earnings conference call, with company executives discussing financial results and business developments.

Why it matters — Earnings calls provide investors and analysts with direct updates on the company's financial performance, pipeline progress, and strategic direction.

Allogene Therapeutics Q2 Earnings Call Highlights

MarketBeat · 12 Aug 2026neutral

Allogene Therapeutics held its Q2 2026 earnings call, detailing progress on its ALPHA3 lymphoma study, FDA designations for cema-cel, published renal cell carcinoma data for ALLO-316, and plans to release initial data from its ALLO-329 autoimmune program by year-end.

Why it matters — ALLO watchers would care because these updates indicate the company is advancing multiple pipeline programs across oncology and autoimmune indications, with key data readouts expected soon.

Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update

GlobeNewsWire · 12 Aug 2026neutral

Allogene Therapeutics reported its financial results for the second quarter ended June 30, 2026, and provided corporate updates on its AlloCAR T product development for cancer and autoimmune disease. The announcement was made on August 12, 2026.

Why it matters — A watcher would want an update on Allogene's clinical progress and financial position as reflected in its quarterly corporate and business update.

Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update

GlobeNewsWire · 4 Aug 2026neutral

Allogene Therapeutics announced it will release its second quarter 2026 financial results and provide a business update on August 12, 2026, after the market closes. A live webcast and conference call will follow the announcement.

Why it matters — The financial results and business update will provide the most current information on the company's financial position and progress of its AlloCAR T product pipeline for cancer and autoimmune disease.

FAQ

Frequently asked questions about ALLO stock

What is the ALLO stock price forecast for 2026-2027?

The 12 Wall Street analysts covering Allogene Therapeutics, Inc. have a median 12-month price target of $9, with estimates ranging from $4 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ALLO stock a buy right now?

Of the 12 analysts covering Allogene Therapeutics, Inc., 11 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Allogene Therapeutics, Inc. 79 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ALLO?

As at 15 Aug 2026, Allogene Therapeutics, Inc. ranks 79 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (87 of 100).

Will ALLO stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +339.0% from the last close, and Ticker Nerd's factor model ranks Allogene Therapeutics, Inc. 79 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ALLO stock forecast for 2030?

No analyst covering Allogene Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ALLO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $14 over the next 12 months.

How has ALLO stock performed over the past year?

Allogene Therapeutics, Inc. returned +91.6% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Allogene Therapeutics, Inc. do?

Allogene Therapeutics Inc. is a clinical-stage biotechnology company focused on developing investigational allogeneic chimeric antigen receptor T cell (AlloCAR T) therapies for cancer and autoimmune diseases.

What is the latest news on ALLO?

The most recent item we track (Zacks Investment Research, 13 Aug 2026): "Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs". Allogene Therapeutics narrowed its Q2 loss as research and development costs declined, while a stronger cash position extended its projected runway into 2029. The company's quarterly earnings beat estimates on the lower R&D spending.

Company

About Allogene Therapeutics, Inc.

Allogene Therapeutics Inc. is a clinical-stage biotechnology company focused on developing investigational allogeneic chimeric antigen receptor T cell (AlloCAR T) therapies for cancer and autoimmune diseases. These 'off-the-shelf' products aim to provide faster, more reliable, and scalable cell therapy options compared to autologous approaches, leveraging healthy donor T cells engineered with multiplex gene-editing and proprietary lymphodepletion technologies. Key programs include cemacabtagene ansegedleucel (cema-cel) for frontline large B-cell lymphoma, ALLO-316 targeting clear cell renal cell carcinoma, and ALLO-329 for autoimmune conditions, with ongoing pivotal Phase 2 trials like ALPHA3 and RESOLUTION. Allogene Therapeutics Inc. maintains state-of-the-art in-house manufacturing and collaborates with partners such as Cellectis, Servier, and Arbor Biotechnologies to advance its pipeline. Headquartered in South San Francisco, California, the company operates a fully integrated platform from discovery through development, positioning it as a leader in redefining cell therapy accessibility for blood cancers, solid tumors, and autoimmune disorders.

CEO Dr. Zachary J. Roberts M.D., Ph.D. · 150 employees · United States · https://allogene.com